Register for free to listen to this article
Listen with Speechify
0:00
1:00
LOUISVILLE, K.Y.—PGXL Laboratories, a provider ofpharmacogenetic testing and interpretive services, recently announced that ithas established a collaborative partnership with AutoGenomics Inc., a developerof an automated, microarray-based multiplexing diagnostic platform, whereinthey will utilize this platform—the automated INFINITI analyzer—for severaldifferent personalized medicine applications.PGXL plans to utilize the INFINITI Warfarin and CYP450 2C19Assay and the INFINITI KRAS-BRAF test.
 
PGXL Labs was the first CLIA-certified lab in the country toconduct pharmacogenetic tests. It provides pharmacogenetic testing and interpretiveservices and developed one of the first commercial CYP2C9/VKORC1 tests foraccurate anticoagulant dosing. Along with its clinical practice, PGXL performscontract research for manufacturers of pharmaceuticals and medical equipment.
 
 
"The automation provided by the AutoGenomics' INFINITIAnalyzer will enhance workflow in our laboratories," said Mark Linder,executive vice president of operations and co-founder of PGXL Labs, in astatement. "With their comprehensive menu of molecular applications in thepharmacogenetics arena, we have found AutoGenomics to be a very suitablepartner in meeting our emerging testing needs."
 
 
A privately held company based in Vista, Calif.,AutoGenomics' technology can be used to assess disease signatures with novel genomicand proteomic markers in the area of genetic disorders, infectious disease,cancer and pharmacogenetics.
 
"We are excited to partner with PGXL Labs, who havepioneered in bringing the benefits of pharmacogenetics testing to patientsacross the country," stated Ramanath Vairavan, senior vice president ofAutoGenomics. "The versatility of our BioFilmChip Microarray technology allowsus to rapidly develop new test applications to meet the evolving needs incompanion diagnostic testing and enable PGXL Labs to expand the array of personalizedmedicine tests."

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue